Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Miranda Bailey, Ajibola Abioye, George Morgan, Tom Burke, MSc, Tim Disher, Stephen Brown, Ashley Bonner, Eleonore Herquelot, Ludovic Lamarsalle, Fanny Raguideau

Blood (2019) 134 (Supplement_1): 2167.

https://doi.org/10.1182/blood-2019-131721

Published: 2019

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

https://doi.org/10.1182/blood-2019-131939

Published: 2019

Journal Articles

Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic Diseases

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Anqi Zhu, MS, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 390.

https://doi.org/10.1182/blood-2019-121343

Published: 2019

Journal Articles

Family Studies of Whim Syndrome

David C. Dale, MD, Emily Dick, BA, Merideth L. Kelley, MSc, Vahagn Makaryan, MD, Jim Connelly, MD, Audrey Anna Bolyard, RN, BS

Blood (2019) 134 (Supplement_1): 215.

https://doi.org/10.1182/blood-2019-126234

Published: 2019

Journal Articles

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

Pamela Allen, MDMSc, Esther Kim, Amy Ayers, MPH, Mary Jo Lechowicz, MD

Blood (2019) 134 (Supplement_1): 4043.

https://doi.org/10.1182/blood-2019-131626

Published: 2019

Journal Articles

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Tayyab Rehan, MBBS, Muhaddis Ejaz Ahmad, MD, Syeda Sabeeka Batool, MBBS, MD, Muhammad Abdullah Yousaf, MBBS, MD, Maaz Ahmed Yusufi, MD, Saif Ur Rehman, MBBS, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Zainab Ijaz, Awais Ijaz, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4442.

https://doi.org/10.1182/blood-2019-127452

Published: 2019

Journal Articles

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Miguel A. Escobar, MD, Linda Shaffer, Mark Holguin, MD, Timothy McCavit, MD, Sandeep K. Rajan, MD, Novinyo Amega, MD

Blood (2019) 134 (Supplement_1): 4923.

https://doi.org/10.1182/blood-2019-122949

Published: 2019

Journal Articles

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Caique Pereira de Moura Martins, MDcal Student, João Vítor Ternes Rech, MDcal Student, Lee I-Ching, MD, Giovanna Steffenello Durigon, MD, Joanita Angela Del Moral, MD, Mirella Rodrigues Oliveira, MD, Bruno Vieira Dias, Maria Claudia Santos, PhD, Andressa Oliveira Martin Wagner, André Guedes Vieira

Blood (2019) 134 (Supplement_1): 5038.

https://doi.org/10.1182/blood-2019-132259

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Ibraheem H. Motabi, MD, Shahid Iqbal, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Belal Albtoosh, BSc, RN, Nawal Faiez Alshehry, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD

Blood (2018) 132 (Supplement 1): 5181.

https://doi.org/10.1182/blood-2018-99-114037

Published: 2018

Journal Articles

Repeated Transfusion of Granulocytes to Control Multidrug-Resistant Pseudomonas Aeruginosa Sepsis in Haploidentical Hematopoietic Stem Cell Transplant Patients during Pre-Engraftment Stage

Yixin Hu, MD, Ruonan Sun, Jun Lu, MD, Peifang Xiao, MD, Jie Li, MD, Defei Zheng, MD, Shaoyan Hu, MD PhD

Blood (2018) 132 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2018-99-117832

Published: 2018

Journal Articles

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Jia Ruan, Peter Martin, Paul Christos, Leandro Cerchietti, Wayne Tam, Bijal Shah, Stephen J. Schuster, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo-Vidal, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard

Blood (2018) 132 (19): 2016–2025.

https://doi.org/10.1182/blood-2018-07-859769

Published: 2018

Journal Articles

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Benjamin Tillman, MD, James Michael Pauff, MD PhD, Gowri Satyanarayana, MD, Mahsa Sharifi Talbott, PharmD, Jeremy Warner, MD MS

Blood (2017) 130 (Supplement 1): 3460.

https://doi.org/10.1182/blood.V130.Suppl_1.3460.3460

Published: 2017

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository

Tait D. Shanafelt, MD, Neil E. Kay, MD, Curtis A. Hanson, MD, Sameer A. Parikh, MD, Sara J Achenbach, Aaron Norman, Kari G Chaffee, MS, Susan Marie Schwager, Timothy G. Call, MD, Susan L Slager, PhD

Blood (2017) 130 (Supplement 1): 831.

https://doi.org/10.1182/blood.V130.Suppl_1.831.831

Published: 2017

Journal Articles

Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study

Janet L. Kwiatkowski, MD, Alexis A Thompson, MD MPH, John Rasko, MBBS, PhD, Suradej Hongeng, MD, Gary J. Schiller, MD, Usanarat Anurathapan, Marina Cavazzana, MD PhD, Phoebe Joy Ho, Christof von Kalle, MD, Morris Kletzel, MD MBA, Philippe Leboulch, MD, Elliott Vichinsky, MD, Briana Deary, Mohammed Asmal, MD PhD, Mark C. Walters, MD

Blood (2017) 130 (Supplement 1): 360.

https://doi.org/10.1182/blood.V130.Suppl_1.360.360

Published: 2017

NARROW

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic Diseases

Family Studies of Whim Syndrome

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Repeated Transfusion of Granulocytes to Control Multidrug-Resistant Pseudomonas Aeruginosa Sepsis in Haploidentical Hematopoietic Stem Cell Transplant Patients during Pre-Engraftment Stage

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository

Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only